Abbott Laboratories ABT

What the company does

Abbott Laboratories is a large-cap company in the Healthcare sector (Medical Devices), with a market value of $179.4B, based in the USA.

It employs about 122,000 people and has been listed since Jan 13, 1978.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Cheap or expensive? priced in line with its group

Its price-to-earnings (P/E) is 38.6 versus 36.9 for the median of the Healthcare sector in our universe (25 companies) — priced in line with its group.

Revenue is growing 14% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 19.2 — they expect higher earnings.

The average analyst price target is 118.64, 14% above the current price (their view, not ours).

The stock sits at 48% of its one-year range (0% = the low, 100% = the high).

The risks

• No risk flags were detected from the data we have.

Strengths

• ✅ Profitable — 7 of every 100 dollars of revenue stays as profit.
• ✅ Most analysts rate it buy (24 vs 0).
• ✅ Pays a dividend (2.5% a year).

What changed this week

Over the past week the stock fell 1.1% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

This week's news

• Abbott Laboratories (ABT) Posted Higher Sensitivity Data For Colorectal Cancer Recurrence Detection finance.yahoo.com · 2026-10-24
  What the article says

  Abbott Laboratories (NYSE:ABT) reported new Beta-CORRECT study data on its Oncodetect test at ESMO 2026. The Beta-CORRECT trial showed a significant sensitivity improvement for detecting colorectal cancer recurrence using circulating tumor DNA. The Oncodetect assay targets low levels of tumor DNA in the bloodstream to… source ↗

• Clinical Laboratory Molecular Diagnostics for Infectious Diseases Market, 2025-2029: Forecast by Application, Place, and Country | Multiplex and Rapid Testing Unlock Growth finance.yahoo.com · 2026-10-23
  What the article says

  Company Logo A 354-page report profiles 36 companies, including Abbott, bioMérieux, Roche and Thermo Fisher, across respiratory, gastrointestinal and meningitis testing in 15 countries — though costs and shifting disease prevalence complicate the outlook Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Clinical Laboratory… source ↗

• Pacemakers Market Forecasts Growth from $5.4 Billion (2025) to $7.5 Billion by 2030, Profiling Medtronic, Abbott, Boston Scientific, Biotronik & 6 Other Key Players finance.yahoo.com · 2026-10-23
  What the article says

  Company Logo 108-Page Report Examines the Shift to Leadless and MRI-Compatible Devices as Rising Arrhythmia Prevalence Drives Demand, While High Procedure Costs, Strict Approvals and Cybersecurity Risks Weigh on Growth Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Pacemakers: Global Markets" has been added to… source ↗

• Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer finance.yahoo.com · 2026-10-23
  What the article says

  Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing1 Building on its leadership in colorectal cancer screening with the Cologuard® test, Abbott is connecting innovations across the cancer care continuum, from early detection to… source ↗

• Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device finance.yahoo.com · 2026-10-22
  What the article says

  Flyte Aviation, Inc. FORT MILL, S.C, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE American: VJET), today announced the first published comparative study evaluating its LockeT suture retention device against a traditional internal vascular closure device… source ↗

• GE HealthCare Technologies (GEHC) vs. DHR and MDT: Can a $23.9B Backlog and AI Innovation Drive a Healthcare Re-Rating? finance.yahoo.com · 2026-10-22
  What the article says

  Is GEHC a good stock to buy? We came across a bullish thesis on GE HealthCare Technologies Inc. on Astute Optics - US's Substack. The thesis was published on September 13th, when the stock was trading at $64.25, and GEHC gained 9.30% since then. The gain appears to reflect improving sentiment toward healthcare stocks… source ↗

What changed since last week

• Risk flag cleared: earnings report coming up.

• No longer a strength: positive free cash flow.

• A new quarterly report was published (quarter ended Sep 30, 2026).